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The soluble glycoprotein sCD14 binds lipopolysaccharide, a complex that activates endothe-
lial cells and that may be crucial in gram-negative sepsis, Therefore, serum sCD14 was analyzed
in 54 patients with gram-negative septic shock and in 26 healthy controls, sCD14 was tested by
ELISA and Western blotting, Patients had higher sCD14 concentrations than controls (median,
3.23 vs. 2.48 #!g/mL, P = .002). Increased levels were associated with high mortality (median, 4.2
#Lg/mL in nonsurvivors vs. 2.8 #!g/mL in survivors, P = .001). sCD14 was found in two isoforms
(49 and 55 kDa) in monocyte cultures. In sera only one of either form was detectable. Controls
had the 49-kDa form, and patients had either the 49- or 55-kDa form, but patients with high
levels of sCD14 had only the 55-kDa form. Twenty-one (53%) of 39 with the 55-kDa form and 8
(57%) of 14 with the 49-kDa form died. Thus, the level of sCD14 but not its biochemical form
had a prognostic value in patients with gram-negative septic shock.
Lipopolysaccharide (LPS) plays a key role in the patho-
physiology of sepsis [I]. The LPS receptor on myeloid cells is
the phosphatidylinositol-Iinked membrane glycoprotein
CD 14 [2]. CD 14 occurs in a membrane-associated form and
as a soluble (s) molecule [3, 4]. sCD 14 is derived from the
monocytic cell line Mono-Mac 6 in two forms [5]: A 48-kDa
form is shed from the membrane of monocytes and Mono-
Mac 6 cells [6, 7], and a 56-kDa form is detectable in meta-
bolically labeled Mono-Mac 6 cells and in sCD 14 purified
from urine [3, 5]. The serum concentration of sCD 14 is ,...., I
millionfold higher than that ofcytokines [8]. Although much
is known about cytokine liberation during experimental en-
dotoxemia or sepsis, little is known about sCD 14 in these
conditions [9-12]. Because CD 14 is the principle LPS recep-
tor, the serum concentration ofsCD 14 may be modified dur-
ing endotoxemia or sepsis. The physiologic role of sCD 14 is
unknown. It could act as a scavenger by neutralizing circu-
lating LPS [13] or, alternatively, it may playa harmful role
by transmitting LPS effects on endothelial cells, which do
not express membrane CD 14 [I4]. Indeed, it was recently
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shown that complexes ofsCD 14 with LPS activate these cells
[14,15].
We measured sequential serum concentrations of sCD 14
in 54 patients with gram-negative septic shock, compared
these with levels in normal controls, and correlated sCD 14
levels with patient outcome. We also determined the bio-
chemical form of serum sCD 14 by Western blotting and
compared it with sCD 14 derived from normal monocytes.
Methods
Patients. The study population comprised 54 patients (33
males, 21 females) with documented gram-negative septic
shock. Their median age was 58 years (range, 7-78). All were
part of a previously described study that compared the efficacy
of J5 hyperimmunoglobulin (n = 22) with standard intrave-
nously (iv) administered IgG (n = 32) (Sandoglobulin; Sandoz
Pharmaceuticals, Basel, Switzerland) [16]. The etiology ofseptic
shock was established by the isolation ofgram-negative bacteria
from blood in 37 patients (69%). Of these, 30 had monomicro-
bial and 7 had polymicrobial bacteremia. Seventeen patients
(3 t%) had documented gram-negative infections with negative
blood cultures. At study entry, the median duration of shock
was 10 h (range, 2-144), the median urinary output was 5 mL/h
(range, 0-190), and the median arterial pH was 7.37 (range,
7.17-7.57). Blood was obtained from all patients at study entry
(day 0), 2 h later (after infusion of either standard or J 5 hyper-
immunoglobulin), and after 24 hand 10 days. In addition, 26
healthy controls (16 men, 10 women; median age, 48 years;
range, 27-72) and 2 women with paroxysmal nocturnal hemo-
globinuria (ages 30 and 38 years) were investigated. Sera were
aliquoted and kept at -70°C until analyzed.
Cells. Mononuclear leukocytes were isolated from heparin-
ized blood by density gradient centrifugation over a ficoll-hypa-
que gradient. Monocytes were purified from mononuclear leu-
kocytes by centrifugation over a continuous Percoll density
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gradient as described [17]. Cells were taken up in RPMI me-
dium with 5% heat-inactivated human AB serum before being
labeled with [35S]methionine or 1251. They were cultured for 48 h
in serum-free HB 101 medium (Hana Biologics, Alameda, CA)
substituted with 2% human serum albumin and 10-8 M 1,250'-
dihydroxyvitamin D3 before the supernatant was harvested for
Western blotting.
Reagents, antibodies to C{J14. and recombinant (r) sCD14.
Goat polyclonal anti-CD 14 antiserum was a gift of R. Ulevitch
(Scripps Research Institute. La Jolla, CA). We used the follow-
ing mouse monoclonal antibodies: MEM 18 (IgG I, which recog-
nizes membrane CDI4 and both forms of sCDI4; gift of V.
Bazil, Prague [3]); RoMo I (IgG2a; IBL, Hamburg, Germany)
[18], 63D3 (lgG I), and 3C I0 (IgG2b; both purified by affinity
chromatography from hybridoma culture supernatants; Ameri-
can Type Culture Collection, Rockville, MD); and My4 (IgG I)
(Coulter, Luton, UK). rsCD 14 was immunopurified on immo-
bilized 3C I0 from culture supernatants of CHO cells that were
transfected with an expression vector containing truncated
CDI4 cDNA (unpublished data).
The endotoxin content in the stock solutions of antibodies
was < 100 pg/rnl., as determined by quantitative limulus assay
(Chromogenix, Molndal, Sweden).
sCD14 depletion from serum. The antibody to CDI4 63D3
was coupled to CNBr-activated Sepharose. Human AB serum
containing 3 JLg/mLsCD 14 was absorbed to antibody-CNBr-Se-
pharose overnight at 4°C. After centrifugation, no sCDI4 was
detected by ELISA or Western blot in the sCD 14-depleted
serum. Heat inactivation of normal serum at 56°C for 30 min
also destroyed sCD 14 immunoreactivity.
Assay for sCD14. Serum concentrations of sCD 14 were de-
termined by sandwich ELISA. Polystyrene plates (Greiner 96-
well; Microlon, Frickenhausen, Germany) were coated over-
night at room temperature with 2 JLg/mLMEM 18 (50 JLL/well).
After plates were washed three times with PBS and 0.05% Tween
(wt/vol), nonspecific binding was blocked for I h at room tem-
perature with 50 JLL/well 0.2 M TRIS-HCI buffer (pH 7.5) with
I%bovine serum albumin (BSA; wt/vol) and 0.05% Tween (wt/
vol). Serum samples diluted 1:150, 1:300, and 1:600 in 0.1 M
phosphate buffer (pH 7.2) with 1% BSA and 0.05% Tween (wt/
vol) or standards (dilutions of sCD 14 isolated from serum by
affinity chromatography [19]; 50 JLL/well) were incubated for 3
h at room temperature. Plates were washed three times with PBS
and 0.05% Tween. Captured sCD 14 was measured by peroxi-
dase-coupled RoMo I (2-h incubation, 50 JLL/well, in 0.1 M
phosphate buffer [pH 7.2] with 1% BSA and 0.05% Tween). The
signal was detected using tetramethylbenzidine and read at A450
in an ELISA reader (Molecular Devices, Palo Alto, CA).
The serum concentration of sCD 14 was the weighted average
of the concentrations determined for each dilution by extrapola-
tion from the linear part (3-40 ng/mL) of the standard sCD 14
curve. When 5 JLg/mL LPS was added to the sCD 14 serum stan-
dard, serum sCD 14 values did not change. For detection of
sCD 14 in monocyte culture supernatants, a similar ELISA with
63D3 as a primary antibody ( 100 JLL, 5 p,g/mL) and peroxidase-
labeled 3C I0 (500 ng/mL) as a capturing antibody was used;
purified rsCD 14 (0.3-10 ng/mL) from CD 14-transfected CHO
cells (unpublished data) served as a standard.
The specificity of the assay was confirmed by the following
experiments. sCD 14-depleted human serum (see above) showed
no reactivity in the ELISA. The immunoreactivity was recov-
ered when the eluted sCD 14 was added back to the depleted
serum. In addition, the specificity of the second peroxidase-la-
beled antibody was tested by adding it along with unlabeled
CD 14 antibody My4 to normal and sepsis sera. My4 competi-
tively inhibited the binding of RoMo I and of 3C I0 (data not
shown).
Effect of standard and J5 hyperimmunoglobulin on sCD14
determination. Patients were treated with standard iv IgG (200
mg/kg) or the same dose of an anti-Lf'S hyperimmunoglobulin
(15) within 2 h of diagnosis of septic shock. The sCDI4 content
of the immunoglobulins given and their influence on sCD 14
serum values were evaluated. Standard IgG. at a twofold higher
concentration than the serum IgG level measured after patients
received therapy ( 12 mg/ml.), contained 100 ng/mL sCD 14. J 5
hyperimmunoglobulin at 12 mg/ml. contained 5 ng/mL
sCD 14. When either immunoglobulin preparation was added to
sCD 14 standard pooled human serum or sCD 14-free serum, the
optical densities of the preparations increased by the amount of
sCDI4 in standard IgG or J5 hyperimmunoglobulin.
sCD 14 levels were determined in the 26 healthy controls. The
median serum concentration ofsCDI4 was 2.48 JLg/mL(range,
1.75-2.90), and intra- and interindividual coefficients of varia-
tion were 12%and 23%, respectively (n = 5, repeated measure-
ments at 0, 2, 24, and 240 h).
SDS-PAGE and Western blotting. Serum samples were di-
luted to contain 3 ng of sCD 14/ I0 JLL and were denatured by
boiling for 5 min in 0.5 M TRIS-HCI containing 5%SDS, 2.5%
glycerol, and 0.0 I% bromphenol blue (sample buffer). Dena-
tured proteins and prestained molecular mass standards (Bio-
Rad, Glattbrugg, Switzerland) were electrophoresed (200 V,
500 rnA) for 60 min in 7.5% polyacrylamide gels under nonre-
ducing conditions and transferred for 60 min (100 V, 500 rnA)
onto Immunlite membranes (Bio-Rad) presoaked in 25 mM
TRIS and 192 mM glycine transfer buffer (TBS; pH 8.3) using a
wet transblot system (Bio-Rad). Membranes were incubated
overnight at 4°C in TBS containing 7.5% dry milk to reduce
nonspecific protein binding and washed twice with TBS and
0.05% Tween (TTBS). They were then incubated for 3 h at room
temperature on a rocking platform with the monoclonal anti-
body to CD 14 (3C I0), diluted I:400 in TTBS containing I%dry
milk or with polyclonal goat anti-CD 14 antiserum diluted
I: 1000. After being washed three times in TTBS, the mem-
branes were incubated for 2 h at room temperature with alkaline
phosphatase-conjugated goat anti-mouse IgG (I :3000; Bio-
Rad) or mouse anti-goat IgG (1:10,000; Sigma, St. Louis) in
TTBS containing I% dry milk. The membranes were then
washed three times with TTBS, incubated for 5 min with 5 mL
of chemoluminescent substrate solution (adamantyl dioxetane
phenyl phosphate; Bio-Rad) and exposed to Kodak X-Omat
films for 10-30 min.
Labeling with [35S] methionine. Monocytes were incubated
for 48 h in medium with 5% heat-inactivated AB serum. CDI4-
transfected CHO cells were cultured in serum-free RPMI me-
dium containing G418 (Geneticin; Boehringer, Mannheim,
Germany). Both cell types were washed and kept for I h in
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NOTE. Dataare median (range) sCDI4 determination with ELISA.
* n = 26.
Table 1. Serum concentrations of soluble (s) COl4 during and
after septic shock.
~55
~49
4321
46
69
97
monocyte
rsCD14 sCD14
vivors showed significantly higher median sCD 14 concentra-
tions than survivors. This difference was significant at study
entry (P = .00 I) and 2 h later but not after 1 and 10 days.
The seD 14 level remained predictive for a high mortality
when age and TNF-a were included in a multivariate analy-
sis (P < .01).
Relationship between sCDl4 and clinical parameters or
cytokines. The earliest measure of sCD 14 correlated in-
versely with mean arterial pressure at that time (P = .03) but
did not correlate with duration of shock at entry (P = .90) or
with urinary output (P = .86). In addition, it did not corre-
late with TNF-a (P = .77), interleukin (IL)-I,8 (P = .44),
IL-6 (P = .79), interferon (IFN)-')' (P = .95), or IFN-a (P =
.69). Serum levels of these cytokines have been described
[II, 12].
Isoforms ofsCDl4. The monocytic cell line Mono-Mac 6
releases two sCDl4 forms [5], and in sCDl4 purified from
urine two forms are identified under reducing conditions [3,
8]. However, the expression of two CD 14 isoforms has not
been seen in normal monocytes, which are the major source
of serum sCD 14. We therefore analyzed culture superna-
tants of membrane or metabolically labeled monocytes by
immunoprecipitation and compared them with immuno-
blots of 48-h monocyte culture supernatants (figure 1). The
smaller (49 kDa) form ofsCDl4 was derived from the mem-
brane, since it was the only molecule detectable in superna-
tants of I 251-labeled monocytes (figure I, lane 2). In contrast,
both the larger (55 kDa) and to a lesser extent the smaller
forms were found in supernatants of metabolically labeled
cells (figure I, lane 3). This suggests that the 55-kDa form
has an intracellular origin without membrane attachment.
Figure 1. Biochemical analysis ofsCO 14. By lane: I, supernatant
containing [35S]methionine-labeled recombinant sCO 14; 2, super-
natant from 125I-labeled monocytes after overnight culture; 3, su-
pernatant ofmonocytes after overnight metabolic labeling: 4, West-
ern blot of 48-h serum-free monocyte culture supernatant.
p
.001
.048
.11
.12
Nonsurvivors
(n = 29)
4.21 (1.06-9.95)
3.89 (1.54-10.10)
4.23 (1.93-14.42)
3.94 (2.51-5.69)
sCDI4 (#Lg/mL)
Survivors
(n = 25)
2.77 (1.15-5.64)
2.44(0.79-8.40)
3.41 (1.94-8.15)
3.03 (0.95-9.89)
2.48 (1.75-2.90)
Results
sCDl4 concentrations in sera ofpatients with gram-negative
septic shock. Serum sCD 14 concentrations were higher in
the 54 patients with gram-negative septic shock than in 26
healthy controls (median, 3.23 vs. 2.48 JLg/mL; P = .002).
Among the 54 patients with gram-negative septic shock, 29
(53.8%) died. The clinical course of the patients has been
described [16]. A high sCDl41evei at the onset of shock was
associated with poor outcome. As shown in table 1, nonsur-
methionine-free medium supplemented with 2% dialyzed fetal
calf serum before addition of 100 JLCi of[35S]methionine (Amer-
sham Laboratories, Arnersham, UK). After overnight culture,
the supernatant was harvested, centrifuged at 100,000 g for 30
min at 4°C; Nonidet P-40 and phenylmethylsulfonyl fluoride
(Sigma) were added at final concentrations of 0.5% and 2 mM,
respectively. For preclearing, the supernatant was incubated 30
min at 4°C with protein G-Sepharose (Pharmacia, Piscataway,
NJ) in the presence of normal serum. After centrifugation, the
supernatant was first incubated for 60 min at 4°C with 3CIO
and then for 30 min at 4°C with protein G-Sepharose. The
immunoprecipitate was washed three times in 50 mM TRIS,
150 mM NaCl, and 5 mM EDTA buffer (pH 7.3). The sample
was taken up in buffer and then denatured and electrophoresed
in a 7.5%SOS-polyacrylamide gel as described above. Gels were
fixed for 30 min in Amplify solution (Amersham Laboratories,
Arnersharn, UK) and then washed in distilled water, dried, and
autoradiographed.
Labeling with /25/. Freshly isolated monocytes (2.5 X 106)
were washed three times with PBS, iodinated for 15 min at room
temperature with 500 JLCi of Na, 1251, and Iodobeads (Pierce,
Rockford, IL) in 6-well culture plates, washed again with PBS,
and cultured overnight in RPMI medium with 5% heat-inacti-
vated human AB serum. The chase medium was then harvested
and processed as described for the [35S]methionine-Iabeled su-
pernatant.
Statistics. Patient groups and controls were compared by
Mann-Whitney test. The relationship between different sero-
logic parameters was evaluated by Wilcoxon rank correlation
test. The effect of sCD 14, tumor necrosis factor-a (TNF-a), and
age on mortality was studied by multivariate analysis ofvariance
(Superanova: Abacus, Berkeley, CA)
Serum sample
Study entry
2 h afterstudy entry
Day I
Day 10
Controls"
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Figure 2. Western blots from sera. By lane: I. nonspecific (ns)
binding. blot with alkaline phosphatase-conjugated second anti-
body; 2. serum from healthy control; 3, serum from paroxysmal
nocturnal hemoglobinuria (PNH) patient; 4-7. sera from sepsis pa-
tients at study entry (lanes 4 and 5. 55-kDa sCD14. survivor and
nonsurvivor, respectively; lanes 6 and 7. 49-kDa sCD 14. survivor
and nonsurvivor, respectively).
Finally. in Western blots of serum-free monocyte culture su-
pernatants. the 55-kDa form was clearly seen; the smaller
forms gave only a weak signal (figure 1, lane 4). To docu-
ment the existence of the two CD 14 isoforms, the immuno-
precipitate from metabolically labeled culture supernatant of
CD 14-transfected CHO cells is shown on lane 1 in figure 1.
In this supernatant. which was very rich in sCD 14 (2 ILg/
ml.), the upper band (55 kDa) was stronger than the 49-kDA
band and even a third intermediate form ofsCDl4 could be
detected.
Western blot ofsera. After recognizing that rsCD 14 and
monocyte culture-derived CD 14 both exist in two molecular
forms, we analyzed human sera to see if it also contained
both forms. For this purpose, Western blots were made with
26 sera from healthy controls and with sera from the 54 study
patients. Serum from 1 patient gave no signal in Western
blot; therefore, the analysis includes 53 patients. As shown
in lane 2 offigure 2, the 49-kDa form ofsCDl4 was found in
serum from healthy volunteers. In contrast, patients with
septic shock had either the 49- or the 55-kDa form at study
onset, provided that their sCD 14 level remained <3.5 ILg/
mL (figure 2 shows two examples of the 49-kDa form. lanes
6 and 7). An sCDl41evei >3.5 ~g/mLwas exclusively asso-
ciated with the 55-kDa form ofsCDl4 (figure 2, lanes 4 and
5). The difference in molecular mass was also seen when a
polyclonal instead of a monoclonal antibody was used for
immunoblotting (data not shown). In addition, sera from
patients with paroxysmal nocturnal hemoglobinuria (who
ns control PNH
Figure 3. Relationship between sCD14concentration and molec-
ular forms. Left: 1:::., 26 healthy controls, 14 sepsis patients with
49-kDa form (6 survivors [0], 8 nonsurvivors [.]). Right: 2 pa-
tients with paroxysmal nocturnal hemoglobinuria (0) and 39 sepsis
patients with 55-kDa form (18 survivors [0], 21 nonsurvivors [.]).
Serum from I of 54 patients did not give a signal in Western blot.
10 •
sCD14 •J.lg/ml
•8
6 <> ~.~
<>~4 _.~
2 ;0 ~
0
49 55
sCD14 Form (kDa)
lack membrane CD 14 and therefore cannot release the
smaller form of sCD 14) had the 55-kDa form exclusively
(figure 2, lane 3).
Relationship between sCD14 molecular form and concentra-
tion. To determine clinical conditions associated with pre-
dominance of either form of sCD 14, patients were grouped
by sCD 14 form and serum concentrations at onset of shock.
Elevated sCD 14 concentrations were associated with a 55-
kDa sCDI4 (figure 3). Patients with 55-kDa sCDI4 had me-
dian sCDl4 concentration of 3.43 ILg/mL (range, 1.41-
9.95); those with the 49-kDa form had a median sCDl4 of
2.28 ~g/mL (range, 1.06-2.90; P < .00 I). The molecular
form ofsCD 14 by itselfwas not associated with high mortal-
ity; 21 (53%) of 39 with 55-kDa sCDl4 and 8 (57%) of 14
with the 49-kDa form died (figure 3). All 26 healthy controls
had 49-kDa sCDl4 (figure 3). Both patients with paroxysmal
nocturnal hemoglobinuria had elevated levels of 55-kDa
CD 14 in their serum.
Immunoblot of CD14 from sera of patients during sepsis.
To detect a possible switch from one molecular form of
sCD 14 to the other, sera from 4 patients were analyzed con-
secutively at study entry and 2 and 24 hand 10 days later
(figure 4; 2 patients with 49-kDa sCD 14 [A, C] and 2 with
>3 ILg/mL 55-kDa seD 14 [B, D]). In figure 4, patients in the
upper row survived; those in the lower row died. Each pa-
tient had the same form of sCD 14 throughout the observa-
tion period, that is, no switch in CD 14 isoforms was ob-
served.
.- 55
.- 49
76
sepsis
5432
97
69
46
150
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Discussion
Figure 4. Western blots and sCDI4 concentrations during and
after septic shock. A and B, Survivors with 49- and 55-kDa forms,
respectively. C and D, Nonsurvivors with 49- and 55-kDa forms,
respectively. Far right of Band D: nonspecific binding in serum
with alkaline phosphatase-conjugated second antibody.
In the present study, serum concentrations and biochemi-
cal forms of sCD 14 were investigated in patients with gram-
negative septic shock. They had elevated serum sCD 14 con-
centrations. In addition, the CD 14 derived from normal
monocytes was found in 49- and 55-kDa forms that originate
from the cell membrane and the intracellular space. In
serum, only a single form was detectable. High levels of
sCDI4 were associated with expression of the 55-kDa form.
The serum concentration but not the isoform of sCD 14 was
predictive for death.
Soluble CD 14 is spontaneously released by the Mono-
Mac 6 cell line, by monocytes, macrophages, and granulo-
cytes [5, 7. 17, 20]. After release, sCDl4 circulates in the
bloodstream [8]. Whereas the serum concentration of
sCD 14 is constant in normal persons (see Methods), we
found increased levels in patients with gram-negative septic
shock. This could be due to a reduced sCD 14 clearance or
alternatively to enhanced liberation. The former is unlikely,
since there was no relationship between urinary output and
sCD 14 concentration. The latter probably occurs during sep-
sis. The stimulus for sCD 14 liberation may be LPS itself or a
cytokine. We found that LPS enhances sCD 14 release from
normal monocytes in vitro (unpublished data). In contrast,
we found no effect of TNF-a, IL-I fl, IL-6, or IFN-')" on
sCD14 release in vitro [I 7].
The pathophysiologic significance of an increased sCD 14
concentration in septic shock is unknown, but it is associated
with increased mortality. sCD 14 promotes LPS binding to
endothelial cells [15]. The ensuing activation of these cells
may be detrimental and thus may explain the worse progno-
sis in patients with increased sCD 14. This relationship sug-
gests that serum levels of sCD 14 may be crucial for the fate
of endothelial cells.
The existence of two forms of sCD 14 has been docu-
mented in immunoprecipitates isolated from urine [3]. We
sought to find if the two isoforms are also detectable in
serum. In earlier studies. only the smaller form was detected
in monocytes [6, 20]. Therefore, we investigated the cellular
mechanisms of release by cells that are the major source of
sCD 14. For this purpose, we analyzed supernatants ofmono-
cytes by Western blotting and after membrane or metabolic
labeling. We detected both forms.
The larger form predominated in supernatants of normal
48-h cultured monocytes. This conclusion is based on the
Western blot analysis of concentrated supernatants. Since
the cultures were serum-free, a contribution of serum CD 14
could be excluded. In addition, the metabolic labeling re-
vealed that in overnight cultures, the 55-kDa form was
mainly synthesized. The origin of this larger form is un-
known. Because it is slightly larger than the well-described
membrane CDI4 (54 kDa) [5], it may be released as a pre-
cursor before processing and attachment of the glycosyl
phosphatidylinositol (GPI) anchor. This mechanism has
been described for several other GPI-linked proteins [21).
Moreover, the immunoblot of sera from our patients with
paroxysmal nocturnal hemoglobinuria, which lacked mem-
brane CD 14, showed the 55-kDa form exclusively. We also
found that the smaller form was derived from the membrane,
since it was the only isoform detected in the supernatant
after membrane labeling of viable monocytes. The 49-kDa
form is smaller than membrane CD 14, which confirms its
proteolytic cleavage. In case of shedding by a GPI-specific
phospholipase C, the molecular mass of membrane and
sCD 14 would be identical. In addition, Bazil and Strominger
[6] found that protease inhibitors reduced the release of
membrane-derived small sCD 14.
Sera from patients with gram-negative septic shock and
controls had one of the two sCD 14 isoforms. In Western
blots of patients with an sCD 14 >3.5 ~g/mL, the 55-kDa
2.29 2.99 2.01 2.81 3.13 3.61 3.5 4.511 CD14 ug,ml
B
2.28 2.56 2.53 2.51 6.24 5.67 4.119 4.89 CD14 ug/ml
97
C
46
69
69
A
46
97
150
150
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form was detected exclusively. In contrast, sera from healthy
volunteers and from patients with sCD 14 <3.5 JLg/mL con-
tained either form. This difference was not an artifact; it ap-
peared with a constant load of 3 ng of sCD 14 per slot in the
polyacrylamide gel. As outlined above, in healthy volunteers
the smaller isoform of sCD 14 is membrane derived, and the
larger form is from the intracellular space. One could argue
that strong cell activation in septic patients results in the
depletion of membrane CD 14. However, these cells could
probably still secrete unprocessed 55-kDa CD 14. In con-
trast, cells with normal surface CD 14 may serve as reservoir
for the shedding of the small isoform. Under culture condi-
tions, normal monocytes preferentially released the 55-kDa
isoform, yet normal serum exclusively contained the 49-kDa
form. This could indicate that a large pool ofcells other than
monocytes (e.g., macrophages or granulocytes) mainly con-
tribute the 49-kDa form. In patients from whom we consecu-
tively tested sCD 14 forms after septic shock, we found no
changes from higher to lower molecular mass forms. Thus,
the mechanisms that regulate the secretion of the isoforms of
sCD 14 remain unknown.
In conclusion, the serum level of sCD 14 was a prognostic
marker in gram-negative septic shock. The functional conse-
quences of the elevated sCD 14 concentration should be ana-
lyzed in an in vitro or in vivo model.
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